Josh Levine

Confluence: Culture, technology, and business.

[Josh Levine @JoshConfluence]

Lessons in Bias for Machine Learning:
Algorithms are only as good as their human instructors
https://t.co/OCXdZEuJMO #AI #MachineLearning

[Josh Levine @JoshConfluence]

‘Do no harm’, attributed to the original Hippocratic Oath, is for physicians. If private equity firms had their own maxim for ethics it might look like this: ‘Insulate yourself from the consequences of your actions’. #healthcare #privateequity #LBO https://t.co/2kCPEgwnBW

[Josh Levine @JoshConfluence]

Lofty soul, inspired talent, and the greatest bricklayer in history. https://t.co/iTnFucA5TD #Florence #Architecture #Morricone

[Josh Levine @JoshConfluence]

Preview. #SolarEclipse2024

[Josh Levine @JoshConfluence]

MIT economist @davidautor: "Recognizing this [AI's] potential, we should ask not what AI will do to us, but what we want it to do for us." https://t.co/q8OCx3TVsJ #AI

[Josh Levine @JoshConfluence]

Data centers are an essential part of the businesses for 40 leading operators and suppliers of digital infrastructure. Together, they represent more than one-third of the #Nasdaq-100's weighting. #datacenters #AI $AAOI $RXT https://t.co/PmThMCcUim

[Josh Levine @JoshConfluence]

Buying in anticipation of a short squeeze adds complicated tactical & speculative dimensions to what is already a challenging task. #shortselling #shortsqueeze $ALLO $BTAI $STEM https://t.co/7QMxrNn0x9

[Josh Levine @JoshConfluence]

Big VC-backed startups use predatory pricing to drive rivals out of the market; don't necessarily need to recoup their losses to succeed. Objective is to create perception of potential recoupment to entice investors. #venturecapital $UBER https://t.co/50YoAXDalT

[Josh Levine @JoshConfluence]

Top IPOs in 2022-23 were small-caps (all biotech) that raised sufficient capital to advance their pipelines over the next 24-36 months. Biggest IPO losers: overwhelmingly <$100M mc with barely enough cash to last until early '24. $GNLX $GPCR $APGE $SGMT https://t.co/SIgimJc58w

[Josh Levine @JoshConfluence]

For 1H 2023, 1,019 companies (avg. mc: $234M) in Third Stream Research's industry groups recorded an average gain of +12.0%. An emerging narrative indicates the gap between small growth and the market's leaders is primed to narrow. $ANAM $SGTX $INMN https://t.co/Y1Um57DhYr

[Josh Levine @JoshConfluence]

Amidst a dynamic deal landscape for #dermatologic companies, we explore if there are still compelling opportunities among smaller firms in this lucrative field. $SMTI https://t.co/U9QZABQPa3

[Josh Levine @JoshConfluence]

Coincident with consumer sentiment’s rebound off a historical low level this year, performance data on cos in our universe (mktcap<$1B, covering TMT, Biotech, Health/LifeSci, Medtech & Cleantech) signals increasing bullishness for #emerginggrowth stocks. https://t.co/1snvcKWXKO

[Josh Levine @JoshConfluence]

What consumer confidence and stock price trends tell us about mean regression for emerging growth companies. https://t.co/1snvcKWXKO

[Josh Levine @JoshConfluence]

June 2023 Digest: Sizing Up Growth Stocks / eMagin This $EMAN / Watchlist Update $ORGS $PRPH / ‘Finfluencers’ vs. Pros. Despite surge in mega-techs and onset of S&P 500 bull market, our data on #emerginggrowth stocks indicate animal spirits remain tepid. https://t.co/x3DY9xMJMT

[Josh Levine @JoshConfluence]

Given the record of consolidation in the #3dprinting industry, investors should be skeptical about the latest round involving $SSYS, $DDD, $DM and $NNDM. https://t.co/pWGbpuELJW

[Josh Levine @JoshConfluence]

Third Stream Research issues an Update Report on ProPhase Labs $PRPH with a Strong Buy recommendation for long-term market outperformance. #biotech #genomics https://t.co/8xFk7bSlkI

[Josh Levine @JoshConfluence]

Mechanization and automation allowed larger companies to take increased market share, according to a new study by Spencer Kwon from Harvard and his collaborators. #automation #megacap https://t.co/jxbJQFYNrv

[Josh Levine @JoshConfluence]

David Booth, founder and chair of Dimensional Fund Advisors, asks ChatGPT: “Is it safer to trust the market price mechanism than rely on an AI model to find mispricing in stocks and bonds?” Answer: Don't trust AI over the wisdom of the crowd. #ai https://t.co/EXuSOAStPf

[Josh Levine @JoshConfluence]

Our monthly/quarterly/annual digests explore investment trends in the emerging growth universe, highlight the performance of the 1,000+ companies tracked by Third Stream Research, and focus on our expanding watch list. https://t.co/FwNBfpCZm6

[Josh Levine @JoshConfluence]

Of the 544 biotech cos tracked by Third Stream Research, 248 are down >50% over past year, 2/3 of which are currently nanocaps. Massive drawdown since mid-2021 was too indiscriminate. One prospect caught our attention amid the wreckage. $ORGS https://t.co/7zkyQhRqRe